Assessment of adverse events associated with triptans - Methods of assessment influence the results

Headache

Volumn 44, Issue 10, 2004, Pages 978-982

  Sheftell, Fred D ^a,b   Feleppa, Michele ^c   Tepper, Stewart J ^b,d   Rapoport, Alan M ^b,e   Ciannella, Luciana ^c   Bigal, Marcelo E ^b,f  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c G RUMMO HOSPITAL   (Italy)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Methods of assessment; Side effects; Tolerability; Triptans

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; ELETRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ABDOMINAL PAIN; ADULT; ARTICLE; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; ITALY; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NEUROLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SIDE EFFECT; SLEEP DISORDER; SWEATING; THORAX DISEASE; TREMOR; UNITED STATES;

EID: 8844285858     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04191.x     Document Type: Article

References (18)

1. Matchar DB, Young WB, Rosenerg J, et al. Multispecialty consensus on diagnosis and treatment of headache: pharmacological management of acute attacks. Neurology. 2000;54. http://www.aan.com/public/practiceguidelines/03. pdf.
2. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations: how to match patients and products. CNS Drugs. 2003;17:431-447.
3. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(suppl 1):3-9.
4. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
5. Sheftell FD, Bigal ME, Tepper SJ, Rapoport AM. Patterns of use of triptan in a tertiary care migraine population [abstract]. Cephalalgia. 2003;23:714.
6. Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol. 2001;58:1479-1480.
7. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders cranial neuralgia and facial pain. Cephalalgia. 1988;8:1-96.
8. Silberstein SD, Lipton RB, Sliwwski M. Classification of daily and near daily headaches: field trial of revised IHS criteria. Neurology. 1996;47:871-875.
9. Welch KM, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia. 2000;20:687-695.
10. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003;2:123-132.
11. Robbins L. Frequent triptan use: observations on safety issues. Headache. 2004;44:178-182.
12. Tfelt-Hansen P, Block G, Dahlof C, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765-786.
13. Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block GA, Lines C. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache. 1998;38:737-747.
14. Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia. 2002;22:416-423.
15. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002;22:453-461.
16. Dowson AJ, Charlesworth BR, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs. 2003;17:839-851.
17. Berry DC, Knapp P, Raynor DK. Provision of information about drug side-effects to patients. Lancet. 2002;359:853-854.
18. Li Bassi L, Bertele V, Garattini S. European regulatory policies on medicines and public health needs. Eur J Public Health. 2003;13:246-251.